Trial Profile

A pilot study to investigate whether adding maraviroc to existing therapy has any effect for people with HIV and fatty liver disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Maraviroc (Primary)
Indications HIV-1 infections
Focus Adverse reactions
Acronyms HEPMARC

Most Recent Events

26 Oct 2022 Results assessing feasibility of add-on maraviroc in people with well-controlled HIV and NAFLD presented at the 16th International Congress on Drug Therapy and HIV Infection
03 Feb 2022 Status changed from active, no longer recruiting to completed.
08 Oct 2020 Results presented at the 15th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com